Association between serum osteoprotegerin level and mortality in kidney transplant recipients - a prospective observational cohort study.
cardiovascular disease
chronic kidney disease-mineral and bone disorder
kidney transplant
osteoprotegerin
outcomes
vascular calcification
Journal
Transplant international : official journal of the European Society for Organ Transplantation
ISSN: 1432-2277
Titre abrégé: Transpl Int
Pays: Switzerland
ID NLM: 8908516
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
revised:
07
12
2020
received:
29
10
2020
accepted:
17
02
2021
pubmed:
20
2
2021
medline:
3
7
2021
entrez:
19
2
2021
Statut:
ppublish
Résumé
Paradoxically, higher serum levels of osteoprotegerin (OPG: a vascular calcification inhibitor) have been associated with increased arterial stiffness, risk of cardiovascular disease and all-cause mortality. A few studies reported that post-transplant OPG levels are associated with mortality in kidney transplant (KT) recipients. In this study, this association was assessed in a cohort of prevalent KT recipients, adjusting for previously untested potential confounders, including fibroblast growth factor 23 (FGF23) and interleukin 6 (IL-6). Socio-demographic and clinical parameters, medical and transplant history, and laboratory data were collected from 982 prevalent KT recipients. The association between serum OPG and all-cause mortality over a 6-year follow-up period was examined using Kaplan-Meier survival curves and multivariable-adjusted Cox regression models. Participants with high serum OPG were more likely female, older, deceased donor KT recipients and have more comorbidity, lower eGFR, higher FGF23, higher IL-6, and longer dialysis vintage. Each 1 pmol/l higher serum OPG level was associated with a 49% higher risk of mortality (hazard ratio (HR) [95% confidence interval (CI)]: 1.49 [1.40-1.61]). This association persisted after adjusting for confounders (HR [95% CI]: 1.20 [1.10-1.30]). In conclusion, serum OPG was associated with all-cause mortality independent of several novel confounders in prevalent KT recipients.
Substances chimiques
Biomarkers
0
FGF23 protein, human
0
Osteoprotegerin
0
Fibroblast Growth Factor-23
7Q7P4S7RRE
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
844-854Subventions
Organisme : Foundation for Prevention in Medicine
Organisme : Egészségügyi Tudományos Tanács
ID : 206/09
Organisme : Hungarian Kidney Foundation
Organisme : Országos Tudományos Kutatási Alapprogramok
ID : F-68841
Organisme : Országos Tudományos Kutatási Alapprogramok
ID : HUMAN-MB08-A-81231
Organisme : Hungarian Society of Hypertension
Organisme : Hungarian Society of Nephrology
Informations de copyright
© 2021 Steunstichting ESOT. Published by John Wiley & Sons Ltd.
Références
Komenda P, Yu N, Leung S, et al. Secular trends in end-stage renal disease requiring dialysis in Manitoba, Canada: a population-based study. CMAJ Open 2015; 3: E8.
Ojo A. Addressing the global burden of chronic kidney disease through clinical and translational research. Trans Am Clin Climatol Assoc 2014; 125: 229.
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
Ushigome H, Sakai K, Suzuki T, et al. Kidney transplantation for patients on long-term hemodialysis. Transpl Proc 2008; 40: 2297.
Kovacs AZ, Molnar MZ, Szeifert L, et al. Sleep disorders, depressive symptoms and health-related quality of life-a cross-sectional comparison between kidney transplant recipients and waitlisted patients on maintenance dialysis. Nephrol Dial Transplant 2011; 26: 1058.
Jansz TT, Bonenkamp AA, Boereboom FTJ, van Reekum FE, Verhaar MC, van Jaarsveld BC. Health-related quality of life compared between kidney transplantation and nocturnal hemodialysis. PLoS One 2018; 13: e0204405.
Nascimento MM, Hayashi SY, Riella MC, Lindholm B. Elevated levels of plasma osteoprotegerin are associated with all-cause mortality risk and atherosclerosis in patients with stages 3 to 5 chronic kidney disease. Braz J Med Biol Res 2014; 47: 995.
Pichler G, Haller MC, Kainz A, Wolf M, Redon J, Oberbauer R. Prognostic value of bone- and vascular-derived molecular biomarkers in hemodialysis and renal transplant patients: a systematic review and meta-analysis. Nephrol Dial Transplant 2017; 32: 1566.
Moe SM, Reslerova M, Ketteler M, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 2005; 67: 2295.
Rochette L, Meloux A, Rigal E, et al. The Role of Osteoprotegerin in Vascular Calcification and Bone Metabolism: The Basis for Developing New Therapeutics. Calcif Tissue Int 2019; 105: 239.
Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337.
Tschiderer L, Willeit J, Schett G, Kiechl S, Willeit P. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS One 2017; 12: e0183910.
Bjerre M, Hilden J, Winkel P, et al. Serum osteoprotegerin as a long-term predictor for patients with stable coronary artery disease and its association with diabetes and statin treatment: A CLARICOR trial 10-year follow-up substudy. Atherosclerosis 2020; 301: 8.
Montañez-Barragán A, Gómez-Barrera I, Sanchez-Niño MD, Ucero AC, González-Espinoza L, Ortiz A. Osteoprotegerin and kidney disease. J Nephrol 2014; 27: 607.
Nemeth ZK, Mardare NG, Czira ME, et al. Serum osteoprotegerin is associated with pulse pressure in kidney transplant recipients. Sci Rep 2015; 5: 14518.
Alderson HV, Ritchie JP, Middleton R, Larsson A, Larsson TE, Kalra PA. FGF-23 and Osteoprotegerin but not Fetuin-A are associated with death and enhance risk prediction in non-dialysis chronic kidney disease stages 3-5. Nephrology 2016; 21: 566.
Collado S, Coll E, Nicolau C, et al. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function. BMC Nephrol 2017; 18: 290.
Ramirez-Sandoval JC, Casanova I, Villar A, Gomez FE, Cruz C, Correa-Rotter R. Biomarkers Associated with Vascular Calcification in Peritoneal Dialysis. Perit Dial Int 2016; 36: 262.
Bargnoux AS, Dupuy AM, Garrigue V, Deleuze S, Cristol JP, Mourad G. Renal transplantation decreases osteoprotegerin levels. Transpl Proc 2006; 38: 2317.
Hjelmesaeth J, Ueland T, Flyvbjerg A, et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol 2006; 17: 1746.
Svensson M, Dahle DO, Mjøen G, et al. Osteoprotegerin as a predictor of renal and cardiovascular outcomes in renal transplant recipients: follow-up data from the ALERT study. Nephrol Dial Transplant 2012; 27: 2571.
Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimbürger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505.
Durlacher-Betzer K, Hassan A, Levi R, Axelrod J, Silver J, Naveh-Many T. Interleukin-6 contributes to the increase in fibroblast growth factor 23 expression in acute and chronic kidney disease. Kidney Int 2018; 94: 315.
Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int 2012; 82: 737.
Wolf M, Molnar MZ, Amaral AP, et al. Elevated Fibroblast Growth Factor 23 is a Risk Factor for Kidney Transplant Loss and Mortality. J Am Soc Nephrol 2011; 22: 956.
Molnar MZ, Nagy K, Remport A, et al. Inflammatory Markers and Outcomes in Kidney Transplant Recipients. Transplantation 2017; 101: 2152.
Czaya B, Faul C. FGF23 and inflammation-a vicious coalition in CKD. Kidney Int 2019; 96: 813.
Singh S, Grabner A, Yanucil C, et al. Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease. Kidney Int 2016; 90: 985.
Fragoso A, Silva AP, Gundlach K, Büchel J, Neves PL. Magnesium and FGF-23 are independent predictors of pulse pressure in pre-dialysis diabetic chronic kidney disease patients. Clin Kidney J 2014; 7: 161.
Molnar MZ, Nagy K, Remport A, et al. Association Between Serum Leptin Level and Mortality in Kidney Transplant Recipients. J Ren Nutr 2017; 27: 53.
Ronai KZ, Szentkirályi A, Lazar AS, et al. Association of symptoms of insomnia and sleep parameters among kidney transplant recipients. J Psychosom Res 2017; 99: 95.
Nitta K. Fibroblast growth factor 23 and cardiovascular disease in patients with chronic kidney disease. Renal Replace Therapy 2018; 4: 31.
Gaipov A, Cseprekal O, Potukuchi PK, et al. Association between malnutrition-inflammation score and risk of subsequent self-reported bone fractures in prevalent kidney transplant recipients. Osteoporos Int 2019; 30: 611.
Gaipov A, Jackson CD, Talwar M, et al. Association Between Serum Prealbumin Level and Outcomes in Prevalent Kidney Transplant Recipients. J Ren Nutr 2019; 29: 188.
Bernardi S, Toffoli B, Bossi F, et al. Circulating osteoprotegerin is associated with chronic kidney disease in hypertensive patients. BMC Nephrol 2017; 18: 219.
Discacciati A, Bellavia A, Lee JJ, Mazumdar M, Valeri L. Med4way: a Stata command to investigate mediating and interactive mechanisms using the four-way effect decomposition. Int J Epidemiol 2018; 48: 15.
Szulc P, Hofbauer LC, Heufelder AE, Roth S, Delmas PD. Osteoprotegerin serum levels in men: correlation with age, estrogen, and testosterone status. J Clin Endocrinol Metab 2001; 86: 3162.
Kudlacek S, Schneider B, Woloszczuk W, Pietschmann P, Willvonseder R. Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone 2003; 32: 681.
Fahrleitner-Pammer A, Dobnig H, Piswanger-Soelkner C, et al. Osteoprotegerin serum levels in women: correlation with age, bone mass, bone turnover and fracture status. Wien Klin Wochenschr 2003; 115: 291.
Kim CS, Bae EH, Ma SK, et al. Association of Serum Osteoprotegerin Levels with Bone Loss in Chronic Kidney Disease: Insights from the KNOW-CKD Study. PLoS One 2016; 11: e0166792.
Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432.
Udell JA, Morrow DA, Jarolim P, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol 2014; 63: 2421.
Poelzl G, Trenkler C, Kliebhan J, et al. FGF23 is associated with disease severity and prognosis in chronic heart failure. Eur J Clin Invest 2014; 44: 1150.
Kestenbaum B, Sachs MC, Hoofnagle AN, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2014; 7: 409.
Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Investig 2011; 121: 4393.
Jean G, Bresson E, Terrat JC, et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009; 24: 948.
Nakahara T, Kawai-Kowase K, Matsui H, et al. Fibroblast growth factor 23 inhibits osteoblastic gene expression and induces osteoprotegerin in vascular smooth muscle cells. Atherosclerosis 2016; 253: 102.
Abedini S, Holme I, März W, et al. Inflammation in renal transplantation. Clin J Am Soc Nephrol 2009; 4: 1246.
Matsubara K, Stenvinkel P, Qureshi AR, et al. Inflammation modifies the association of osteoprotegerin with mortality in chronic kidney disease. J Nephrol 2009; 22: 774.
Benz K, Hilgers KF, Daniel C, Amann K. Vascular Calcification in Chronic Kidney Disease: The Role of Inflammation. Int J Nephrol 2018; 2018: 4310379.
Prasad N, Jaiswal A, Agarwal V, et al. FGF23 is associated with early post-transplant hypophosphataemia and normalizes faster than iPTH in living donor renal transplant recipients: a longitudinal follow-up study. Clin Kidney J 2016; 9: 669.
Fitzpatrick J, Kim ED, Sozio SM, et al. Calcification Biomarkers, Subclinical Vascular Disease, and Mortality Among Multiethnic Dialysis Patients. Kidney Int Rep 2020; 5: 1729.